Your browser doesn't support javascript.
loading
Evaluating the role of RAD52 and its interactors as novel potential molecular targets for hepatocellular carcinoma.
Li, Ping; Xu, YanZhen; Zhang, Qinle; Li, Yu; Jia, Wenxian; Wang, Xiao; Xie, Zhibin; Liu, Jiayi; Zhao, Dong; Shao, Mengnan; Chen, Suixia; Mo, Nanfang; Jiang, Zhiwen; Li, Liuyan; Liu, Run; Huang, Wanying; Chang, Li; Chen, Siyu; Li, Hongtao; Zuo, Wenpu; Li, Jiaquan; Zhang, Ruoheng; Yang, Xiaoli.
Afiliación
  • Li P; 1Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin, Guangxi China.
  • Xu Y; 4College & Hospital of Stomatology Guangxi Medical University, Nanning, Guangxi China.
  • Zhang Q; 5Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi China.
  • Li Y; 1Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin, Guangxi China.
  • Jia W; 8Department of Pathophysiology, Guangxi Medical University, Nanning, Guangxi China.
  • Wang X; Genetic and Metabolic Central Laboratory, The Maternal and Children Health Hospital of Guangxi, Guangxi, China.
  • Xie Z; Medical Science Laboratory at Liuzhou Worker's Hospital, Liuzhou, Guangxi China.
  • Liu J; 1Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin, Guangxi China.
  • Zhao D; 6College of Pharmacy, Guangxi Medical University, Nanning, Guangxi China.
  • Shao M; 3Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi China.
  • Chen S; 1Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin, Guangxi China.
  • Mo N; 1Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin, Guangxi China.
  • Jiang Z; 4College & Hospital of Stomatology Guangxi Medical University, Nanning, Guangxi China.
  • Li L; 5Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi China.
  • Liu R; 1Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin, Guangxi China.
  • Huang W; 1Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin, Guangxi China.
  • Chang L; 1Center of Diabetic Systems Medicine, Guangxi Key Laboratory of Excellence, Guilin Medical University, Guilin, Guangxi China.
  • Chen S; 8Department of Pathophysiology, Guangxi Medical University, Nanning, Guangxi China.
  • Li H; 3Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi China.
  • Zuo W; 3Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi China.
  • Li J; 3Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi China.
  • Zhang R; 3Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi China.
  • Yang X; 3Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi China.
Cancer Cell Int ; 19: 279, 2019.
Article en En | MEDLINE | ID: mdl-31719794
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Cell Int Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Cell Int Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido